162 related articles for article (PubMed ID: 10199241)
1. Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
Flandre P
AIDS; 1999 Feb; 13(3):430-1. PubMed ID: 10199241
[No Abstract] [Full Text] [Related]
2. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
3. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
;
AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
7. A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
Roca B; Olmos P; Mínguez C; Arnedo A; Usó J; Teruel C; Segarra M; Sáez-Royuela A; Simón E
Scand J Infect Dis; 1998; 30(4):426-8. PubMed ID: 9817530
[TBL] [Abstract][Full Text] [Related]
8. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
9. Focusing on the second phase of plasma HIV-1 RNA clearance.
Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
[No Abstract] [Full Text] [Related]
10. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
11. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
Girard PM; Schneider V; Dehée A; Mariot P; Jacomet C; Delphin N; Damond F; Carcelain G; Autran B; Saimot AG; Nicolas JC; Rozenbaum W
AIDS; 2001 Jan; 15(2):275-7. PubMed ID: 11216939
[No Abstract] [Full Text] [Related]
12. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
13. Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Morlat P; Marimoutou C; Dequae-Merchadou L; Pellegrin I; Mercié P; Neau D; Beylot J; Dabis F
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):255-60. PubMed ID: 10839661
[TBL] [Abstract][Full Text] [Related]
14. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
[No Abstract] [Full Text] [Related]
15. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
[TBL] [Abstract][Full Text] [Related]
16. Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
Montaner JS; Harris M; Mo T; Harrigan PR
AIDS; 1998 Jul; 12(11):1398-9. PubMed ID: 9708426
[No Abstract] [Full Text] [Related]
17. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
18. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
Bouscarat F; Levacher M; Landman R; Muffat-Joly M; Girard PM; Saimot AG; Brun-Vézinet F; Sinet M
AIDS; 1998 Jul; 12(11):1267-73. PubMed ID: 9708405
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
[TBL] [Abstract][Full Text] [Related]
20. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
Raboud JM; Montaner JS; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg MA; Robinson P; Myers M; Hall D
AIDS; 1998 Sep; 12(13):1619-24. PubMed ID: 9764780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]